Agilent Technologies Inc
XMUN:AG8
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
A
|
Agilent Technologies Inc
XMUN:AG8
|
US |
|
Larsen & Toubro Ltd
NSE:LT
|
IN |
Agilent Technologies Inc
Agilent Technologies Inc stellt die Instrumente her, die Wissenschaftler und Labortechniker zum Testen, Messen und Analysieren von Proben verwenden. Zu seinen Produkten gehören analytische Instrumente, Laborsoftware, Verbrauchsmaterialien sowie Reparatur- und Unterstützungsleistungen. Kunden setzen sie in der Arzneimittelentwicklung, in klinischen und diagnostischen Laboren, in der Lebensmittelsicherheit, bei Umweltprüfungen und in der chemischen Forschung ein. Das Unternehmen verkauft Geräte wie Chromatographie- und Spektroskopiesysteme sowie die Teile und Chemikalien, die diese Systeme zum Betrieb benötigen. Es erzielt außerdem Einnahmen aus Serviceverträgen, Wartung und Ersatzverbrauchsmaterialien, was nach dem Erstverkauf wiederkehrende Geschäfte schafft. Ein großer Teil von Agilents Umsatz stammt von Laboren, die zuverlässige Instrumente und fortlaufende Unterstützung benötigen statt einmaliger Käufe. Agilent befindet sich in der Mitte der Wertschöpfungskette für wissenschaftliche Tests: Das Unternehmen entdeckt in der Regel nicht die Medikamente und betreibt meist nicht die Labore, liefert jedoch die Kernwerkzeuge, auf die diese Kunden angewiesen sind. Das unterscheidet sein Geschäft von vielen industriellen Unternehmen, weil die Nachfrage an langfristig laufende Bedürfnisse für Tests, Qualitätskontrolle und Forschung gebunden ist und nicht an ein einzelnes Endprodukt.
Agilent Technologies Inc stellt die Instrumente her, die Wissenschaftler und Labortechniker zum Testen, Messen und Analysieren von Proben verwenden. Zu seinen Produkten gehören analytische Instrumente, Laborsoftware, Verbrauchsmaterialien sowie Reparatur- und Unterstützungsleistungen. Kunden setzen sie in der Arzneimittelentwicklung, in klinischen und diagnostischen Laboren, in der Lebensmittelsicherheit, bei Umweltprüfungen und in der chemischen Forschung ein.
Das Unternehmen verkauft Geräte wie Chromatographie- und Spektroskopiesysteme sowie die Teile und Chemikalien, die diese Systeme zum Betrieb benötigen. Es erzielt außerdem Einnahmen aus Serviceverträgen, Wartung und Ersatzverbrauchsmaterialien, was nach dem Erstverkauf wiederkehrende Geschäfte schafft. Ein großer Teil von Agilents Umsatz stammt von Laboren, die zuverlässige Instrumente und fortlaufende Unterstützung benötigen statt einmaliger Käufe.
Agilent befindet sich in der Mitte der Wertschöpfungskette für wissenschaftliche Tests: Das Unternehmen entdeckt in der Regel nicht die Medikamente und betreibt meist nicht die Labore, liefert jedoch die Kernwerkzeuge, auf die diese Kunden angewiesen sind. Das unterscheidet sein Geschäft von vielen industriellen Unternehmen, weil die Nachfrage an langfristig laufende Bedürfnisse für Tests, Qualitätskontrolle und Forschung gebunden ist und nicht an ein einzelnes Endprodukt.
Beat and raise: Agilent said Q2 revenue, margin and EPS all came in above the high end of guidance, and it raised full-year revenue and EPS outlooks.
Strong execution: Management credited the quarter to Ignite operating system gains, pricing, productivity improvements, and better commercial execution across the business.
Broad demand: Pharma, chemicals and advanced materials, diagnostics and clinical, and forensics all performed well, while food and academia/government were weaker.
Instruments strong: Instrument orders again met or exceeded revenue, marking the ninth straight quarter of book-to-bill at or above 1, helped by replacement cycles and share gains.
Guidance up: Full-year core revenue growth guidance moved to 4.5% to 6%, EPS to $6 to $6.10, and operating margin expansion to 85 basis points at the midpoint.
Watch points: Management flagged softer food demand, pressure from the Middle East conflict, and China weakness in academia/government and food, but said the business remains stable overall.
Geschäftsleitung
Rodney Gonsalves is the Vice President and Chief Accounting Officer at Agilent Technologies Inc. He specializes in finance and accounting functions, including financial reporting, auditing, and compliance. Gonsalves has extensive experience in leading and managing finance teams, focusing on delivering financial insights and maintaining rigorous standards of accuracy and efficiency. He plays a critical role in Agilent Technologies' financial health, ensuring that all accounting practices adhere to the highest standards and regulations. Prior to his role at Agilent, he gathered substantial experience in varied finance roles across different organizations, contributing significantly to strategic financial planning and execution.
John Kohl is the Senior Vice President, General Counsel, and Secretary at Agilent Technologies, Inc. He plays a pivotal role in overseeing the global legal affairs of the company, providing strategic guidance on legal, regulatory, and compliance matters. Kohl has been instrumental in shaping and navigating Agilent's legal strategies and policies, ensuring adherence to increasing regulatory requirements across various markets. With a robust legal background and significant experience in the technology and healthcare sectors, John Kohl has contributed to Agilent's growth and success in the industry. His leadership extends beyond legal counsel, as he participates in key executive decisions, corporate governance, and risk management initiatives. Kohl joined Agilent Technologies with a wealth of experience gained from his previous roles in prestigious law firms and other corporations. His expertise spans various areas, including intellectual property, mergers and acquisitions, and legal risk management, making him a valuable asset to Agilent's executive team.
With a robust legal background and significant experience in the technology and healthcare sectors, John Kohl has contributed to Agilent's growth and success in the industry. His leadership extends beyond legal counsel, as he participates in key executive decisions, corporate governance, and risk management initiatives.
Kohl joined Agilent Technologies with a wealth of experience gained from his previous roles in prestigious law firms and other corporations. His expertise spans various areas, including intellectual property, mergers and acquisitions, and legal risk management, making him a valuable asset to Agilent's executive team.
Bret M. DiMarco serves as the Senior Vice President, General Counsel, and Secretary of Agilent Technologies Inc. In his role, DiMarco oversees Agilent's global legal, intellectual property, and compliance functions. He plays a critical role in guiding the company through complex legal landscapes, ensuring compliance with regulations, and protecting Agilent's intellectual property assets. DiMarco's leadership is instrumental in supporting Agilent's business goals and maintaining its ethical standards across its global operations. His extensive experience and expertise in legal affairs contribute significantly to the company's strategic initiatives and growth.
Dominique P. Grau is a notable executive at Agilent Technologies Inc. He serves as the Senior Vice President of Quality and Regulatory Affairs for the company. In his role, he oversees global quality assurance, regulatory affairs, and compliance functions. His responsibilities include ensuring that Agilent’s products adhere to the highest quality standards and meet regulatory requirements across different markets. Mr. Grau has extensive experience in quality and regulatory roles, contributing significantly to the life sciences and diagnostics sectors. His expertise is integral to maintaining Agilent's reputation for excellence in providing trusted analytical solutions and ensuring the company’s products contribute to customer success. In addition to his current role, Dominique P. Grau's career includes various leadership positions, where he has demonstrated his adeptness at managing complex regulatory landscapes and driving improvement initiatives. His educational background and career trajectory underline his commitment to quality and compliance, positioning him as a key figure in Agilent's leadership team.
Mr. Grau has extensive experience in quality and regulatory roles, contributing significantly to the life sciences and diagnostics sectors. His expertise is integral to maintaining Agilent's reputation for excellence in providing trusted analytical solutions and ensuring the company’s products contribute to customer success.
In addition to his current role, Dominique P. Grau's career includes various leadership positions, where he has demonstrated his adeptness at managing complex regulatory landscapes and driving improvement initiatives. His educational background and career trajectory underline his commitment to quality and compliance, positioning him as a key figure in Agilent's leadership team.
Jenipher E. Dalton is an executive at Agilent Technologies Inc., where she holds the position of Vice President, Assistant General Counsel, and Assistant Secretary. In her role, Dalton plays a crucial part in overseeing legal matters and corporate governance at Agilent, a leading global company in the life sciences, diagnostics, and applied chemical markets. Her responsibilities typically involve managing legal risks, supporting business strategies, providing legal guidance on transactions, and ensuring regulatory compliance. Through her expertise and leadership, Dalton contributes to Agilent’s mission of advancing the quality of life by providing cutting-edge technology solutions.
Philip Binns is recognized for his role at Agilent Technologies, where he has made significant contributions. Serving as Senior Vice President, he oversees the Chemical & Energy, Food, and Pharma business unit in the company's Life Sciences and Applied Markets Group. Under his leadership, these sectors have successfully advanced in developing and deploying innovative solutions that meet varied industry needs. Binns' strategic insights and management acumen have played a crucial role in navigating complex market landscapes and expanding Agilent's position within these critical industries. His extensive experience in technology and market strategy continues to serve as a valuable asset to Agilent Technologies.
Dr. Simon May is a prominent figure at Agilent Technologies Inc., where he holds a significant leadership role. As of the latest information, he serves as the Vice President and General Manager of the Mass Spectrometry Division. Dr. May is responsible for overseeing the strategic direction, development, and global operations of Agilent’s mass spectrometry business, a core area within the life sciences and applied markets. With a strong academic background in chemistry, Dr. May has extensive expertise in analytical instrumentation, having garnered numerous years of experience in the field. Before joining Agilent, he held various roles that contributed to his deep understanding of scientific research and development, as well as business management. Throughout his career at Agilent, Dr. May has been instrumental in driving innovation and advancing the company’s technological capabilities in mass spectrometry. His leadership has been key to enhancing Agilent's position as a leader in providing solutions for complex analytical challenges across various industries, including pharmaceuticals, environmental, and food safety sectors. Dr. May's contributions are recognized within the scientific community and industry, noted for his commitment to promoting scientific excellence and fostering collaborative relationships to advance the capabilities and applications of mass spectrometry technologies.
With a strong academic background in chemistry, Dr. May has extensive expertise in analytical instrumentation, having garnered numerous years of experience in the field. Before joining Agilent, he held various roles that contributed to his deep understanding of scientific research and development, as well as business management.
Throughout his career at Agilent, Dr. May has been instrumental in driving innovation and advancing the company’s technological capabilities in mass spectrometry. His leadership has been key to enhancing Agilent's position as a leader in providing solutions for complex analytical challenges across various industries, including pharmaceuticals, environmental, and food safety sectors.
Dr. May's contributions are recognized within the scientific community and industry, noted for his commitment to promoting scientific excellence and fostering collaborative relationships to advance the capabilities and applications of mass spectrometry technologies.